Core Viewpoint - The Gross Law Firm is notifying shareholders of agilon health, inc. regarding a class action lawsuit due to alleged misleading statements and guidance issued by the company during the specified class period [1][2]. Group 1: Allegations - The complaint alleges that agilon health, inc. issued materially false and/or misleading statements during the class period from February 26, 2025, to August 4, 2025 [1]. - It is claimed that the defendants recklessly provided guidance for 2025 that they knew or should have known was unattainable due to significant industry challenges [1]. - The complaint also states that the defendants overstated the immediate positive financial impact from strategic actions taken to mitigate risk, leading to materially false and misleading statements about the company's business and prospects [1]. Group 2: Class Action Details - Shareholders who purchased shares of AGL during the class period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for March 2, 2026 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ardent Health, Inc. (NYSE: ARDT). Shareholders who purchased shares of ARDT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/ardent-health-inc-loss-submission-form/?id=183129&from=4 CLASS PERIOD: July 18, 202 ...

Group 1 - The analyst expresses caution regarding investments in the pharmaceutical sector due to regulatory uncertainties and unpredictable clinical trial outcomes [1] - The analyst has over 10 years of experience in the investment industry, focusing on small-cap stocks often overlooked by Wall Street [1] - The analyst is a CFA Level III candidate and holds qualifications from the Chartered Institute for Securities and Investment (CISI) [1] Group 2 - The analyst has been featured on major financial platforms such as CNBC, Bloomberg, Nasdaq, and Yahoo Finance [1] - The analyst is involved in private equity transactions, including acquiring and managing businesses [1]

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. for alleged violations of the Securities Exchange Act, specifically for making false and misleading statements regarding its financial reporting [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from July 18, 2024, to November 12, 2025, with a deadline for lead plaintiff appointments set for March 9, 2026 [2]. - The complaint alleges that Ardent Health utilized a 180-day cliff on accounts receivable, allowing the company to report inflated amounts and delay loss recognition, rendering its public statements materially misleading [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although such an appointment is not necessary to participate in any recovery [2][3].

NEW ORLEANS, Jan. 14, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 9, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE: ARDT), if they purchased or otherwise acquired the Company’s securities between July 18, 2024 and November 12, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Middle ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Viewpoint - The Gross Law Firm is notifying shareholders of Agilon Health, Inc. regarding a class action lawsuit due to alleged misleading statements and guidance issued by the company during a specified period [1][3]. Group 1: Allegations - The complaint alleges that Agilon Health's defendants issued materially false and/or misleading statements and failed to disclose critical information during the class period from February 26, 2025, to August 4, 2025 [3]. - Specific allegations include that the defendants recklessly provided guidance for 2025 that they knew or should have known was unattainable due to significant industry challenges [3]. - Additionally, it is claimed that the defendants overstated the immediate positive financial impact from strategic actions taken to mitigate risk, leading to materially false and misleading statements about the company's business and prospects [3]. Group 2: Class Action Details - Shareholders who purchased shares of Agilon Health during the class period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for March 2, 2026 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4]. - Participation in the case incurs no cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [5].

Core Viewpoint - Medline is participating in its first JPMorgan Healthcare Conference as a publicly traded company, indicating a significant milestone for the company and its visibility in the healthcare sector [2]. Group 1: Company Presentation - Jim Boyle, the CEO of Medline, will present, with Mike Drazin, the CFO, joining for the Q&A session, highlighting the leadership's engagement with investors [1]. - Karen King, the Head of Investor Relations, will provide an opening statement, setting the stage for the presentation and emphasizing the importance of investor relations [1][3]. Group 2: Financial Expectations - The company will make forward-looking statements regarding its long-term financial targets, which are based on current expectations but may differ due to various risks and uncertainties [3]. - There will be references to non-GAAP financial measures during the presentation, which will exclude certain items from the financial results reported in accordance with GAAP, providing a clearer picture of the company's financial health [4][5].

PresentationGreat. Thank you all for being here. My name is John Stansel. I'm a member of the health care services equity research team here at JPMorgan. And we're thrilled to be joined by Alignment Healthcare, where we have CEO, John Kao; and CFO, Jim Head. John is going to give a presentation, and then we're going to move to some Q&A after that.John KaoFounder, CEO & Director Thanks, John. Good morning, everybody. Can you guys hear me okay? All right. Let's see here. Let me see if I can figure this out. O ...

Core Insights - Omada Health is presenting for the first time as a public company, highlighting its transition from a private entity to a public one [1] - The company's mission focuses on addressing chronic diseases affecting 156 million Americans, aiming to improve the quality of care provided to these patients [3] Company Overview - Omada Health operates as a "between visit provider," indicating its role in offering healthcare services that supplement traditional medical visits [2] - The company was co-founded by Sean Duffy, who serves as the CEO and Director, emphasizing the leadership's commitment to the healthcare sector [2] Industry Context - The healthcare industry faces significant challenges with chronic diseases, necessitating innovative solutions to improve patient outcomes [3] - The prevalence of chronic diseases in the U.S. presents a substantial market opportunity for companies like Omada Health to deliver targeted care [3]